Across the pond...Nasdaq: KZIA, page-237

The authors for the abstract on Medical management of brain metastases, will correct their publication.
All 3 authors would be well aware of the drugs selected in ALLIANCE study, they will be very embarrassed with their lack of proof reading..

The study arms from the ALLIANCE study is as follows:-
"Experimental: Arm I (CDK gene mutation)Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.Intervention: Drug: Abemaciclib
Experimental: Arm II (PI3K gene mutation)Patients receive PI3K inhibitor GDC-0084 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.Intervention: Drug: PI3K Inhibitor GDC-0084
Experimental: Arm III (NTRK/ROS1 gene mutation)Patients receive entrectinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.Intervention: Drug: Entrectinib"

Regards.